Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Magnet Biomedicine

Request full access

Magnet Biomedicine is revolutionizing human medicine with molecular glues

Boston, United StatesFounded 2021Biotech & Life Sciences

About Magnet Biomedicine

Magnet Biomedicine, founded in 2019, is a biotechnology company focused on advancing the discovery and development of a class of small molecules known as molecular glues. The company officially launched in September 2023 with a $50 million Series A financing round co-led by Newpath Partners and ARCH Venture Partners. The company was established by a distinguished group of scientists, including molecular glue researcher Stuart Schreiber, 2017 Nobel Laureate Michael Rosbash, chemoproteomics pioneer Benjamin Cravatt, human geneticist Richa Saxena, and chemical biologist David Spiegel. This team's collective expertise in chemistry, biology, and genetics forms the scientific backbone of the company.

The company operates in the biopharmaceutical market, specifically focusing on therapeutics that can address historically undruggable protein targets. Its business model centers on the discovery and development of these novel medicines, with a strategy that includes forming partnerships with larger pharmaceutical companies. In a significant milestone, Magnet entered into a collaboration and license agreement with Eli Lilly to discover, develop, and commercialize molecular glue therapeutics for oncology. This deal included substantial upfront and near-term payments, with the potential for over a billion dollars in milestone payments plus royalties.

Magnet Biomedicine's core technology is its proprietary TrueGlue™ discovery platform. This platform utilizes advanced screening technologies, proprietary chemical libraries, and human-biology-driven target selection to rationally design 'TrueGlues'. Unlike many existing approaches that focus on protein degradation, Magnet's technology aims to induce novel protein-protein interactions. These engineered small molecules bring together a disease-relevant target protein and a 'presenter' protein, which can lead to various therapeutic outcomes beyond just degradation, such as inhibiting protein function in a tissue-specific manner or stabilizing proteins. This approach offers the potential to create highly selective drugs that minimize off-target toxicities. The company is initially targeting diseases with strong genetic and clinical validation in areas such as oncology, cardiovascular disease, and immune disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
42
Open positions
1
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Sep 2023 $50M $200M ARCH Venture Partners · Newpath Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Magnet Biomedicine website traffic

Latest recorded traffic for Magnet Biomedicine is 1.8K monthly website visits, up 20% over the last three months. Magnet Biomedicine's team grew 600% over the past year.

Latest monthly visits1.8K 3-month web change+20% 1-year team growth+600%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Magnet Biomedicine in the Boston ecosystem

Live from Dealroom

The Magnet Biomedicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Magnet Biomedicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Magnet Biomedicine’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.